BUSINESS

duration of the extension depends on the time we spend in clinical studies as well as getting an NDA
approval from the FDA. Summaries of patents of our Core Product Candidates and marketed products
as of July 18, 2018 are set forth below:

Summary of U.S. Patents of Our Core Product Candidates

Product

Scope of patent protection

Patent

Expiration

Market commercial
rights of BeiGene

Eligibility
for patent
extension

Zanubrutinib .... Directed to zanubrutinib, a small

2034

molecule BTK inhibitor,
combinations of zanubrutinib with
other therapeutic agents, and its use
for the treatment of hematological
malignancies

Tislelizumab .... Directed to tislelizumab, a

2033

humanized monoclonal antibody
against PD-1, and its use for the
treatment of cancer

Pamiparib ........ Directed to pamiparib, a small

2031

molecule PARP1/2 inhibitor, and its
use for the treatment of cancer,
including glioblastomas and breast
cancer

Lifirafenib ....... Directed to lifirafenib, a small

2031

molecule BRAF inhibitor, and its
use for the treatment of cancer,
including BRAF mutated cancers

All rights in the
U.S.

Yes

All rights in the
field of hematology
in the U.S., and
rights to combine
with our products in
all indications
All rights in the
U.S.

All rights in the
U.S.

Yes

Yes

Yes

— 242 —

